New Epidiolex(R) (CBD) Data Accepted for Presentation at

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 25, 2015 at 9:15 AM

New Epidiolex(R) (CBD) Data Accepted for Presentation at the 69th Annual Meeting of the American Epilepsy Society

LONDON, Nov. 25, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that seven abstracts related to GW programs have been selected for presentation at the upcoming 69^th Annual Meeting of the American Epilepsy Society including data from the physician-led Epidiolex® (cannabidiol or CBD) expanded access program. The meeting will be held December 4-8 in Philadelphia, PA.

"We are pleased to see a significant number of abstracts related to Epidiolex at this year's Annual Meeting for the American Epilepsy Society and believe this reflects the importance of this program within the epilepsy community," stated Justin Gover, GW's Chief Executive Officer. "The new data disclosed in these abstracts from the Epidiolex expanded access program continues to reinforce and support the encouraging signals of efficacy and safety consistent with previous data disclosures. Our four pivotal Phase 3 trials of Epidiolex are now in their advanced stages and we look forward to data from these trials next year."

Epidiolex is an oral formulation of pure plant-derived CBD. GW is undertaking a formal development program for Epidiolex in severe, drug-resistant childhood epilepsy syndromes which include two pivotal Phase 3 trials of Epidiolex in Dravet syndrome and two pivotal Phase 3 trials of Epidiolex in Lennox-Gastaut syndrome. A Phase 3 trial in Tuberous Sclerosis Complex is due to commence shortly.

The following is a list of Epidiolex related posters and their presentation times. Additional information on the American Epilepsy Society and presentations at the annual meeting can be found online at www.aesnet.org .


Late-Breaking Abstracts
Poster Number	Title and Presentation Time
3.397	Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program
	Poster Session 3: Monday, Dec 7, 8:00 am - 2:00 pm
3.403	Cannabidiol (CBD) Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex (TSC)
	Poster Session 3: Monday, Dec 7, 8:00am - 2:00 pm
3.404	Cannabidiol Treatment of Refractory Epileptic Spasms: An Open Label Study
	Poster Session 3: Monday, Dec 7, 8:00am - 2:00 pm

Original Abstracts
Poster Number	Title and Presentation Time
2.164	Cannabidiol in Genetic Refractive Epilepsy in Dravet and Non-Dravet Cases
	Poster Session 2: Sunday, Dec 6, 8:00 am - 4:00 pm
2.296	Long-term Efficacy and Tolerability of Add-On Cannabidiol for Drug-Resistant Pediatric Epilepsies
	Poster Session 2: Sunday, Dec 6, 8:00 am - 4:00 pm
2.375	Socioeconomic Characteristics of Patients in the Alabama Study of Cannabidiol (CBD) Use to Treat Epilepsy
	Poster Session 2: Sunday, Dec 6, 8:00 am - 4:00 pm
3.034	Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals' Cannabidiol in the Anticonvulsant Screening Program
	Poster Session 3: Monday, Dec 7, 8:00 am - 2:00 pm

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex^® , which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex^® , which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com .

GW Pharmaceuticals plc (Today) +44 20 3727 1000 Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570 FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway + 44 20 3727 1000

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

EQT Acquires Range Resources: Redefining Gas Markets

A New Chapter in Natural Gas Who would have thought? EQT Corporation, that sturdy old veteran in the natural gas game, finally made its move and snatched up Range Resources, sprinting right out of left field. This merger isn't just about two companies shaking hands; it's about rewriting the entire narrative of America's natural gas landscape. With this acquisition, EQT's...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Minesto Teams Up to Unlock Tidal Power in Maldives

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...